Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
about
Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosisFunctional and Structural Characterization of Purine Nucleoside Phosphorylase from Kluyveromyces lactis and Its Potential Applications in Reducing Purine Content in FoodUrate oxidase purification by salting-in crystallization: towards an alternative to chromatographyCloning, purification, and partial characterization of Bacillus subtilis urate oxidase expressed in Escherichia coli.Airway uric acid is a sensor of inhaled protease allergens and initiates type 2 immune responses in respiratory mucosaUric acid promotes an acute inflammatory response to sterile cell death in miceAdvances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.Clinical applications of drug desensitization in the Asia-Pacific region.Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experienceThe therapeutic potential of adenosine triphosphate as an immune modulator in the treatment of HIV/AIDS: a combination approach with HAART.Site-specific incorporation of unnatural amino acids into urate oxidase in Escherichia coliDevelopment of Therapeutic Chimeric Uricase by Exon Replacement/Restoration and Site-Directed MutagenesisRevisiting the reported signal of acute pancreatitis with rasburicase: an object lesson in pharmacovigilancePitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).New advances in the treatment of gout: review of pegloticaseThe clinical management of tumour lysis syndrome in haematological malignancies.Danger signals activating innate immunity in graft-versus-host disease.Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel.Rasburicase for the treatment of tumor lysis in hematological malignancies.Uric acid and the kidney.Dissolution of extensive urolithiasis: extending the utility of rasburicase can avoid the need for surgical intervention and renal replacement therapy.Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.Spontaneous tumor lysis syndrome in a case of B-cell non-Hodgkin's lymphoma.Cloning and expression of Aspergillus flavus urate oxidase in Pichia pastoris.Treatment of tumor lysis syndrome with the highest known uric acid level.Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.Tumor Lysis Syndrome in Patients with Hematological Malignancies.Isolation, screening and production studies of uricase producing bacteria from poultry sources.Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation.Recombinant production of Aspergillus Flavus uricase and investigation of its thermal stability in the presence of raffinose and lactose.Urate–lowering therapy: uricases
P2860
Q26744390-E7806815-C797-4822-A8C6-96E12814FF8BQ28552877-E3EAFD8E-DE06-4BE5-9422-8C0FDD20A342Q28740308-D8BE99A0-9545-46F3-8292-7C06771EF67FQ33532572-B69EC1B6-5DB5-4EF2-9DDF-03D19982BD4AQ33581103-00F1908D-C33A-4C5E-978C-F22F6598B7B8Q33882855-DD768441-F19A-4B5C-9298-02AC528B0535Q35026721-C03109CE-1F6F-4BDE-985F-539A9229C17DQ35502326-87C3EB90-1959-467A-B52F-338AFFE592BEQ35742173-332C5336-62F9-42E1-A450-E9461F88806DQ35932071-BCF932F7-F514-4B72-9D9F-D65CA3F57BACQ36901647-DD9AF5BF-00A9-4156-8EF8-2587D3F26757Q36939339-44DD0F0C-CAD8-46CD-BF83-B983CA5BE0CEQ36967198-6C69F2E1-E1F4-4916-8BCA-88BF05646CECQ37586944-1F113A26-2845-41D9-9653-3093BC62EFA0Q37815379-E0A8FFC0-8842-4D00-AB7C-BDB0F9FE0941Q37873541-34A0A0F2-60A8-4BE5-8489-384186E79B59Q37875779-142B5A07-613D-4AB2-A518-5DBEE84552E2Q37903768-C1CFC6BD-3087-4363-A1ED-08CFCB0C0A43Q37978342-CA99B0C1-8BB3-4B4B-84B0-BA00DAE1E29AQ38119133-0FDEF156-889E-48DB-8187-9B197E6008B9Q38621925-C2CFCFB4-9BFE-42AD-9666-5AADB0105685Q40793204-D95357C9-0451-4AF3-BEDA-2EB02B1FA3ADQ42565489-3BD3B23B-A397-4137-B8D6-2FC7B14F50F5Q42773757-484D42B4-4A67-45B3-8250-94D4272B0890Q42956399-20F6C34E-D2F9-469E-A34C-BC2DA89C6727Q44201303-37246A41-E076-41EC-861B-5C91D06DFE76Q46949121-4CEA7176-461A-4F98-A5B9-14106009AFFBQ46966911-72B4A544-6976-4631-9AC7-F1335C722E0DQ47104402-472FF85D-2FA2-48DD-9A29-A170C65A0E76Q55428086-94D54D84-2EF8-4AC1-8191-B9787B44B683Q57076772-79462A62-CDEC-4A2D-9618-C653DA76FE76
P2860
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
@ast
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
@en
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
@nl
type
label
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
@ast
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
@en
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
@nl
prefLabel
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
@ast
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
@en
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
@nl
P2860
P921
P3181
P356
P1476
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
@en
P2093
Lisa Cammalleri
Mariano Malaguarnera
P2860
P3181
P356
10.7150/IJMS.4.83
P407
P577
2007-03-02T00:00:00Z